Man Group
CSTL icon

Man Group’s Castle Biosciences CSTL Stock Holding History

Man Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.59M Buy
108,761
+61,623
+131% +$1.37M ﹤0.01% 1443
2026
Q1 		$1.16M Buy
47,138
+35,553
+307% +$1.16M ﹤0.01% 1777
2025
Q4 		$451K Buy
+11,585
New +$373K ﹤0.01% 1918
2025
Q2 		– Sell
-14,514
Closed -$291K – 2206
2025
Q1 		$291K Buy
14,514
+1,212
+9% +$30K ﹤0.01% 1943
2024
Q4 		$354K Buy
+13,302
New +$405K ﹤0.01% 1750
2024
Q3 		– Sell
-9,600
Closed -$209K – 2009
2024
Q2 		$209K Sell
9,600
-13,457
-58% -$300K ﹤0.01% 1882
2024
Q1 		$511K Buy
+23,057
New +$502K ﹤0.01% 1773

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group's CSTL Position: Q2 2026 in Review

Man Group increased its Castle Biosciences (CSTL) stake by 131% in Q2 2026, buying an estimated $1.37M and bringing the position to 108,761 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1443.

Man Group first reported a position in CSTL in Q1 2024 and has held it in 7 quarters since. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Man Group held 108,761 shares of Castle Biosciences worth $2.59M as of Q2 2026.
  • Man Group bought 61,623 Castle Biosciences shares in Q2 2026, an estimated $1.37M.
  • Castle Biosciences made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1443 holding.
  • Man Group first reported a position in Castle Biosciences in Q1 2024 and has held it in 7 quarters since.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.